## Carl J Pepine

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5272914/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	What Is the Role of Assessing Ischemia to Optimize Therapy and Outcomes for Patients with Stable Angina and Non-obstructed Coronary Arteries?. Cardiovascular Drugs and Therapy, 2022, 36, 1027-1038.	2.6	2
2	Concomitant coronary microvascular dysfunction and spontaneous coronary artery dissection resulting in ST-segment elevation myocardial infarction. Journal of Cardiology Cases, 2022, 25, 76-78.	0.5	3
3	Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovascular Research, 2022, 118, 2428-2436.	3.8	6
4	Evaluation of the key prescription sequence symmetry analysis assumption using the calcium channel blocker: Loop diuretic prescribing cascade. Pharmacoepidemiology and Drug Safety, 2022, 31, 72-81.	1.9	7
5	Specialized Proresolving Mediators in Symptomatic Women With Coronary Microvascular Dysfunction (from the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD [WARRIOR]) Tj ETQq1	10178431	4 rg&T /Over
6	lschemia and no obstructive coronary arteries in patients with stable ischemic heart disease. International Journal of Cardiology, 2022, 348, 1-8.	1.7	13
7	Relationship of Psychological Characteristics to Daily Life Ischemia. Psychosomatic Medicine, 2022, Publish Ahead of Print, .	2.0	2
8	Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions. Drugs, 2022, 82, 241-250.	10.9	5
9	Coronary microvascular dysfunction as a chronic inflammatory state: Is there a role for omega-3 fatty acid treatment?. American Heart Journal Plus, 2022, 13, 100098.	0.6	0
10	Gut Microbiome and Neuroinflammation in Hypertension. Circulation Research, 2022, 130, 401-417.	4.5	46
11	Body weight and physical fitness in women with ischaemic heart disease: does physical fitness contribute to our understanding of the obesity paradox in women?. European Journal of Preventive Cardiology, 2022, 29, 1608-1614.	1.8	6
12	RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study. Frontiers in Cardiovascular Medicine, 2022, 9, 821162.	2.4	3
13	Digital health intervention in patients with recent hospitalization for acute heart failure: A systematic review and meta-analysis of randomized trials. International Journal of Cardiology, 2022, , .	1.7	0
14	Efficacy and Safety of MSC Cell Therapies for Hospitalized Patients with COVID-19: A Systematic Review and Meta-Analysis. Stem Cells Translational Medicine, 2022, 11, 688-703.	3.3	13
15	Microvascular Dysfunction as a Systemic Disease: A Review of the Evidence. American Journal of Medicine, 2022, 135, 1059-1068.	1.5	22
16	Identification of a Gut Commensal That Compromises the Blood Pressure-Lowering Effect of Ester Angiotensin-Converting Enzyme Inhibitors. Hypertension, 2022, 79, 1591-1601.	2.7	19
17	Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 851-860.	4.5	5
18	Non-obstructive Plaque and Treatment of INOCA: More to Be Learned. Current Atherosclerosis Reports, 2022, 24, 681-687.	4.8	2

#	Article	IF	CITATIONS
19	Women and atrial fibrillation. Journal of Cardiovascular Electrophysiology, 2021, 32, 2793-2807.	1.7	39
20	Depression phenotype identified by using single nucleotide exact amplicon sequence variants of the human gut microbiome. Molecular Psychiatry, 2021, 26, 4277-4287.	7.9	46
21	Clinical Safety Profile of Transendocardial Catheter Injection Systems: A Plea for Uniform Reporting. Cardiovascular Revascularization Medicine, 2021, 22, 100-108.	0.8	5
22	The Clinical Spectrum of Myocardial Infarction and Ischemia With Nonobstructive Coronary Arteries in Women. JACC: Cardiovascular Imaging, 2021, 14, 1053-1062.	5.3	4
23	Aspirin in Primary Prevention: What Changed? A Critical Appraisal of Current Evidence. American Journal of Cardiology, 2021, 141, 38-48.	1.6	12
24	Left ventricular circumferential strain and coronary microvascular dysfunction: A report from the Women's Ischemia Syndrome Evaluation Coronary Vascular Dysfunction (WISE-CVD) Project. International Journal of Cardiology, 2021, 327, 25-30.	1.7	12
25	Butyrate Regulates COVID-19–Relevant Genes in Gut Epithelial Organoids From Normotensive Rats. Hypertension, 2021, 77, e13-e16.	2.7	45
26	Phytoestrogen blood levels and adverse outcomes in women with suspected ischemic heart disease. European Journal of Clinical Nutrition, 2021, 75, 829-835.	2.9	4
27	Efficacy of Ranolazine for Treatment of Coronary Microvascular Dysfunction—A Systematic Review and Meta-analysis of Randomized Trials. CJC Open, 2021, 3, 101-108.	1.5	12
28	Reply to "Angiotensin-converting enzyme 2, sex differences, and COVID-19: The missing link― International Journal of Cardiology, 2021, 328, 250.	1.7	1
29	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. International Journal of Cardiology, 2021, 326, 131-138.	1.7	13
30	Sex Differences, Aspirin, and Primary Prevention. American Journal of Medicine, 2021, 134, 9-10.	1.5	2
31	Management of Cardiovascular Disease in Kidney Disease Study: Rationale and Design. American Journal of Nephrology, 2021, 52, 36-44.	3.1	2
32	A multiplexed ion-exchange membrane-based miRNA (MIX·miR) detection platform for rapid diagnosis of myocardial infarction. Lab on A Chip, 2021, 21, 3876-3887.	6.0	11
33	Maternal Stroke. Circulation, 2021, 143, 727-738.	1.6	23
34	Preparticipation Cardiac Evaluation Findings in a Cohort of Collegiate Female Athletes. American Journal of Cardiology, 2021, 140, 134-139.	1.6	4
35	Clinician engagement in the ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and) Tj ETQq1	1 0.7843 1.6	14 <sub>2</sub> rgBT /Ove
36	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. Cardio-Oncology, 2021, 7, 10.	1.7	12

#	Article	IF	CITATIONS
37	Does Patient-Physician Gender Concordance Influence Patient Perceptions or Outcomes?. Journal of the American College of Cardiology, 2021, 77, 1135-1138.	2.8	49
38	Prior Oral Contraceptive Use and Longer Term Mortality Outcomes in Women with Suspected Ischemic Heart Disease. Journal of Women's Health, 2021, 30, 377-384.	3.3	4
39	Lactate Dehydrogenase B and Pyruvate Oxidation Pathway Associated With Carfilzomib-Related Cardiotoxicity in Multiple Myeloma Patients: Result of a Multi-Omics Integrative Analysis. Frontiers in Cardiovascular Medicine, 2021, 8, 645122.	2.4	9
40	Reproductive lifespan and incident stroke risk among post-menopausal women: Is it time for sex-specific risk prediction tools?. International Journal of Cardiology, 2021, 328, 218-219.	1.7	3
41	Diagnostic Cardiovascular Imaging and Therapeutic Strategies in Pregnancy. Journal of the American College of Cardiology, 2021, 77, 1813-1822.	2.8	21
42	Sex and gender differences in COVID-19: More to be learned!. American Heart Journal Plus, 2021, 3, 100011.	0.6	33
43	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	10.7	56
44	Management of Women With Acquired Cardiovascular Disease From Pre-Conception Through Pregnancy andÂPostpartum. Journal of the American College of Cardiology, 2021, 77, 1799-1812.	2.8	33
45	A Phase <scp>II</scp> study of autologous mesenchymal stromal cells and câ€kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the <scp>CCTRN CONCERTâ€HF</scp> trial. European Journal of Heart Failure, 2021, 23, 661-674.	7.1	89
46	Management of Women With Congenital or Inherited Cardiovascular Disease From Pre-Conception Through Pregnancy andÂPostpartum. Journal of the American College of Cardiology, 2021, 77, 1778-1798.	2.8	49
47	Depletion of Esteraseâ€Harboring Bacteria Increases Antihypertensive Efficacy of ACE Inhibitor Quinapril. FASEB Journal, 2021, 35, .	0.5	0
48	Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group. European Heart Journal, 2021, 42, 4592-4600.	2.2	84
49	Distinct Gene Expression Profiles in Colonic Organoids from Normotensive and the Spontaneously Hypertensive Rats. Cells, 2021, 10, 1523.	4.1	4
50	Peak Systolic Blood Pressure During the Exercise Test: Reference Values by Sex and Age and Association With Mortality. Hypertension, 2021, 77, 1906-1914.	2.7	8
51	Blood pressure-lowering treatment for the prevention of cardiovascular events in patients with atrial fibrillation: An individual participant data meta-analysis. PLoS Medicine, 2021, 18, e1003599.	8.4	16
52	Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. Pharmacotherapy, 2021, 41, 710-721.	2.6	1
53	Syndrome of Nonobstructive Coronary Artery Diseases: A Comprehensive Overview of Open Artery Ischemia. American Journal of Medicine, 2021, 134, 1321-1329.	1.5	9
54	Rationale and design of the Women's Ischemia Trial to Reduce Events in Nonobstructive CAD (WARRIOR) trial. American Heart Journal, 2021, 237, 90-103.	2.7	51

#	Article	IF	CITATIONS
55	Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genomeâ€Wide Interaction Metaâ€Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies. Clinical Pharmacology and Therapeutics, 2021, 110, 723-732.	4.7	6
56	Acute Pulmonary Embolism During Pregnancy and Puerperium. Mayo Clinic Proceedings, 2021, 96, 2102-2113.	3.0	13
57	Peripheral Blood Biomarkers Associated With Improved Functional Outcome in Patients With Chronic Left Ventricular Dysfunction: A Biorepository Evaluation of the FOCUS-CCTRN Trial. Frontiers in Cardiovascular Medicine, 2021, 8, 698088.	2.4	1
58	Functional heart recovery in an adult mammal, the spiny mouse. International Journal of Cardiology, 2021, 338, 196-203.	1.7	19
59	Coronary endothelial dysfunction appears to be a manifestation of a systemic process: A report from the Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2021, 16, e0257184.	2.5	11
60	A Six-Day, Lifestyle-Based Immersion Program Mitigates Cardiovascular Risk Factors and Induces Shifts in Gut Microbiota, Specifically Lachnospiraceae, Ruminococcaceae, Faecalibacterium prausnitzii: A Pilot Study. Nutrients, 2021, 13, 3459.	4.1	31
61	First and recurrent events in the ISCHEMIA trial: two sides of the same coin. European Heart Journal, 2021, , .	2.2	2
62	Depressive hypertension: A proposed human endotype of brain/gut microbiome dysbiosis. American Heart Journal, 2021, 239, 27-37.	2.7	15
63	Association of coronary microvascular dysfunction and cardiac bridge integrator 1, a cardiomyocyte dysfunction biomarker. Clinical Cardiology, 2021, 44, 1586-1593.	1.8	2
64	Potential of Minocycline for Treatment of Resistant Hypertension. American Journal of Cardiology, 2021, 156, 147-149.	1.6	5
65	Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. American Heart Journal, 2021, 241, 38-49.	2.7	10
66	Relationship between coronary function testing and migraine: results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction project. , 2021, 5, .		0
67	Perfusion, cryopreservation, and nanowarming of whole hearts using colloidally stable magnetic cryopreservation agent solutions. Science Advances, 2021, 7, .	10.3	54
68	Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet, The, 2021, 398, 1803-1810.	13.7	64
69	Somatic versus cognitive depressive symptoms as predictors of coronary artery disease among women with suspected ischemia: The women's ischemia syndrome evaluation. Heart and Mind (Mumbai, India), 2021, 5, 112.	0.6	4
70	Abstract 13833: Cardiac Sympathetic Denervation in Patients With Ventricular Tachycardia or Electrical Storm: A 6 Months Follow-Up. Circulation, 2021, 144, .	1.6	0
71	Abstract 9697: Relation Between Measures of Ventricular Volume/Pressure and Myocardial Damage and Coronary Microvascular Dysfunction Response to Ranolazine. Circulation, 2021, 144, .	1.6	0
72	Acute Stroke During Pregnancy and Puerperium. Journal of the American College of Cardiology, 2020, 75, 180-190.	2.8	52

#	Article	IF	CITATIONS
73	Heart failure with preserved ejection fraction: Similarities and differences between women and men. International Journal of Cardiology, 2020, 304, 101-108.	1.7	18
74	Adverse Pregnancy Outcomes Are Associated with Reduced Coronary Flow Reserve in Women With Signs and Symptoms of Ischemia Without Obstructive Coronary Artery Disease: A Report from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction Study. Journal of Women's Health, 2020, 29, 487-492.	3.3	11
75	Risk and Blood Pressure Control Rates Across the Spectrum of Coronary Artery Disease in Hypertensive Women: An Analysis from The INternational VErapamil SR-Trandolapril STudy (INVEST). Journal of Women's Health, 2020, 29, 158-166.	3.3	1
76	Systolic blood pressure, heart rate, and outcomes in patients with coronary disease and heart failure. ESC Heart Failure, 2020, 7, 124-130.	3.1	5
77	Design, methodology and baseline characteristics of the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD). American Heart Journal, 2020, 220, 224-236.	2.7	15
78	Transcriptomic signature of gut microbiome-contacting cells in colon of spontaneously hypertensive rats. Physiological Genomics, 2020, 52, 121-132.	2.3	20
79	Coronary Vascular Function and Cardiomyocyte Injury. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3015-3021.	2.4	10
80	Assessment of Vascular Dysfunction inÂPatients Without Obstructive CoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2020, 13, 1847-1864.	2.9	105
81	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy HeartÂFailure Patients. JACC: CardioOncology, 2020, 2, 581-595.	4.0	24
82	Association of Factor V Leiden With Subsequent Atherothrombotic Events. Circulation, 2020, 142, 546-555.	1.6	11
83	Left ventricular mass and myocardial scarring in women with hypertensive disorders of pregnancy. Open Heart, 2020, 7, e001273.	2.3	6
84	ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases. Hypertension, 2020, 76, 651-661.	2.7	57
85	Optimal systolic blood pressure and reduced long-term mortality in older hypertensive women with prior coronary events – An analysis from INVESTâ~†. International Journal of Cardiology: Hypertension, 2020, 7, 100052.	2.2	1
86	Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults. Journal of the American Heart Association, 2020, 9, e018233.	3.7	4
87	Would Repurposing Minocycline Alleviate Neurologic Manifestations of COVID-19?. Frontiers in Neuroscience, 2020, 14, 577780.	2.8	8
88	Why are women better protected from COVID-19: Clues for men? Sex and COVID-19. International Journal of Cardiology, 2020, 315, 105-106.	1.7	32
89	Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women. Journal of the American College of Cardiology, 2020, 75, 2602-2618.	2.8	175
90	Even "WISE-R?â€â€"an Update on the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation. Current	t 4.8	6

Atherosclerosis Reports, 2020, 22, 35.

#	Article	IF	CITATIONS
91	Resting coronary velocity and myocardial performance in women with impaired coronary flow reserve: Results from the Women's Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction (WISE-CVD) study. International Journal of Cardiology, 2020, 309, 19-22.	1.7	12
92	Maternal Treatment With Captopril Persistently Alters Gut-Brain Communication and Attenuates Hypertension of Male Offspring. Hypertension, 2020, 75, 1315-1324.	2.7	50
93	Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era. American Journal of Medicine, 2020, 133, 1254-1261.	1.5	5
94	Temporal Trends in Angina, Myocardial Perfusion, and Left Ventricular Remodeling in Women With No Obstructive Coronary Artery Disease Over 1â€Year Followâ€Up: Results From WISE VD. Journal of the American Heart Association, 2020, 9, e016305.	3.7	4
95	Redefining Resistant Hypertension. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005979.	2.2	2
96	Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension. Hypertension, 2020, 75, 1063-1071.	2.7	130
97	Commentary - The ISCHEMIA trial. International Journal of Cardiology, 2020, 304, 1-4.	1.7	7
98	Thiazide Exposure and Cardiovascular Risk in Type 2 Diabetes Mellitus. Hypertension, 2020, 75, e2-e5.	2.7	0
99	Treatment of coronary microvascular dysfunction. Cardiovascular Research, 2020, 116, 856-870.	3.8	114
100	Immune Dysregulation in HFpEF: A Target for Mesenchymal Stem/Stromal Cell Therapy. Journal of Clinical Medicine, 2020, 9, 241.	2.4	11
101	A Cardio-Obstetric Approach toÂManagement of the Complex Pregnant Cardiac Patient. JACC: Case Reports, 2020, 2, 86-90.	0.6	1
102	Myocardial ischemia: From disease to syndrome. International Journal of Cardiology, 2020, 314, 32-35.	1.7	19
103	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women With Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report From WISE (Women's Ischemia Syndrome) Tj ETQq1 1 0.784	-31 <b>4ang</b> BT /	'Ov <b>es</b> lock 10
104	Invasive Functional Assessment in Patients With Angina and Coronary Microvascular Dysfunction. Journal of the American College of Cardiology, 2020, 75, 2550-2552.	2.8	3
105	What is the Real Message of the ISCHEMIA Trial from a Clinician's Perspective?. European Cardiology Review, 2020, 15, e63.	2.2	1
106	N-Terminal pro-B-type natriuretic peptide and coronary microvascular dysfunction in women with preserved ejection fraction: A report from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD) study. PLoS ONE, 2020, 15, e0243213.	2.5	3
107	International prospective cohort study of microvascular angina – Rationale and design. IJC Heart and Vasculature, 2020, 31, 100630.	1.1	6
108	Myocardial Infarction and Persistent Angina With No Obstructive Coronary Artery Disease. JACC: Case Reports, 2020, 2, 9-14.	0.6	0

#	Article	IF	CITATIONS
109	Cell Therapy Strategies With No Safety Concerns and Demonstrated Benefits Warrant Study. Circulation Journal, 2020, 84, 2120-2121.	1.6	0
110	Abstract 16457: Racial/Ethnic Differences in Cardiac Surveillance Evaluation for Cancer Patients Treated With Anthracycline-based Chemotherapy: The Oneflorida Clinical Research Consortium. Circulation, 2020, 142, .	1.6	0
111	Migraine Headache: An Underâ€Appreciated Risk Factor for Cardiovascular Disease in Women. Journal of the American Heart Association, 2019, 8, e014546.	3.7	23
112	Gender in cardiovascular medicine: chest pain and coronary artery disease. European Heart Journal, 2019, 40, 3819-3826.	2.2	47
113	First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients. JACC Basic To Translational Science, 2019, 4, 659-669.	4.1	183
114	Heart Failure With Preserved Ejection Fraction: Is Ischemia Due to Coronary Microvascular Dysfunction a Mechanistic Factor?. American Journal of Medicine, 2019, 132, 692-697.	1.5	45
115	Advances in small-molecule therapy for managing angina pectoris in the elderly. Expert Opinion on Pharmacotherapy, 2019, 20, 1471-1481.	1.8	1
116	Impaired Autonomic Nervous System-Microbiome Circuit in Hypertension. Circulation Research, 2019, 125, 104-116.	4.5	73
117	Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 randomised participants in the new phase of the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), BMI Open, 2019, 9, e028698.	1.9	26
118	Age at Menarche and Risk of Cardiovascular Disease Outcomes: Findings From the National Heart Lung and Blood Instituteâ€5ponsored Women's Ischemia Syndrome Evaluation. Journal of the American Heart Association, 2019, 8, e012406.	3.7	56
119	Prevalence of Coronary Endothelial and Microvascular Dysfunction in Women with Symptoms of Ischemia and No Obstructive Coronary Artery Disease Is Confirmed by a New Cohort: The NHLBI-Sponsored Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction (WISE-CVD), Journal of Interventional Cardiology, 2019, 2019, 1-8.	1.2	22
120	Medical Therapy for Heart Failure Caused by Ischemic Heart Disease. Circulation Research, 2019, 124, 1520-1535.	4.5	115
121	Incidence, prevalence, and predictors of treatmentâ€resistant hypertension with intensive blood pressure lowering. Journal of Clinical Hypertension, 2019, 21, 825-834.	2.0	15
122	β <sub>2</sub> â€Adrenergic Receptor Gene Affects the Heart Rate Response of βâ€Blockers: Evidence From 3 Clinical Studies. Journal of Clinical Pharmacology, 2019, 59, 1462-1470.	2.0	9
123	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002470.	3.6	17
124	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. Circulation Genomic and Precision Medicine, 2019, 12, e002471.	3.6	22
125	Left ventricular concentric remodelling and functional impairment in women with ischaemia with no obstructive coronary artery disease and intermediate coronary flow reserve: a report from the WISE-CVD study. European Heart Journal Cardiovascular Imaging, 2019, 20, 875-882.	1.2	11
126	Sustained Captoprilâ€Induced Reduction in Blood Pressure Is Associated With Alterations in Gutâ€Brain Axis in the Spontaneously Hypertensive Rat. Journal of the American Heart Association, 2019, 8, e010721.	3.7	63

			CHAHONS
127	Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes inÂWomen. Journal of the American College of Cardiology, 2019, 73, 684-693.	2.8	152
128	Magnitude of and Characteristics Associated With the Treatment of Calcium Channel Blocker–Induced Lower-Extremity Edema With Loop Diuretics. JAMA Network Open, 2019, 2, e1918425.	5.9	27
129	Sex and Race/Ethnicity Differences in Atrial Fibrillation. Journal of the American College of Cardiology, 2019, 74, 2812-2815.	2.8	22
130	Complementary Embryonic and Adult Cell Populations Enhance Myocardial Repair in Rat Myocardial Injury Model. Stem Cells International, 2019, 2019, 1-11.	2.5	0
131	Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. European Heart Journal, 2019, 40, 2455-2462.	2.2	85
132	Microglial Cells Impact Gut Microbiota and Gut Pathology in Angiotensin II-Induced Hypertension. Circulation Research, 2019, 124, 727-736.	4.5	89
133	Genome-wide association analysis of common genetic variants of resistant hypertension. Pharmacogenomics Journal, 2019, 19, 295-304.	2.0	16
134	Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction ancillary study. International Journal of Cardiology, 2019, 276, 8-13.	1.7	37
135	Benefit of One Week Immersion in Lifestyle-based Program for Sustainable Improvements in Cardiovascular Risk Factors Over Time. International Journal of Disease Reversal and Prevention, 2019, 2, 10.	0.1	2
136	Hypertension in pregnancy: Taking cues from pathophysiology for clinical practice. Clinical Cardiology, 2018, 41, 220-227.	1.8	47
137	Why names matter for women: MINOCA/INOCA (myocardial infarction/ischemia and no obstructive) Tj ETQq1 1 C	).784314 ( 1.8	rg&T /Overlo
138	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post–myocardial infarction heart failure: Trial rationale and study design. American Heart Journal, 2018, 201, 141-148.	2.7	22
139	Predicted Versus Observed Major Adverse Cardiac Event Risk in Women with Evidence of Ischemia and No Obstructive Coronary Artery Disease: A Report from Women's Ischemia Syndrome Evaluation (WISE). Canadian Journal of Cardiology, 2018, 34, e15.	1.7	0
140	Hypertension Across a Woman'sÂLifeÂCycle. Journal of the American College of Cardiology, 2018, 71, 1797-1813.	2.8	159
141	Myocardial Scar Is Prevalent and Associated With Subclinical Myocardial Dysfunction in Women With Suspected Ischemia But No Obstructive Coronary Artery Disease. Circulation, 2018, 137, 874-876.	1.6	23
142	Intensive blood pressure lowering reduces adverse cardiovascular outcomes among patients with highâ€normal glucose: An analysis from the Systolic Blood Pressure Intervention Trial database. Journal of Clinical Hypertension, 2018, 20, 620-624.	2.0	5
143	Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit <sup>+</sup> ) Tj ETQq1	1 0.78431 4.5	4 rgBT /Ove

#	Article	IF	CITATIONS
145	Prevalence, Causes, and Predictors of 30â€Day Readmissions Following Hospitalization With Acute Myocardial Infarction Complicated By Cardiogenic Shock: Findings From the 2013–2014 National Readmissions Database. Journal of the American Heart Association, 2018, 7, .	3.7	28
146	High sensitivity cardiac troponin T and I and risk stratification of patients with stable CHD: Is it time to incorporate this in routine clinical practice?. International Journal of Cardiology, 2018, 250, 266-267.	1.7	0
147	Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure. Clinical Science, 2018, 132, 701-718.	4.3	328
148	Social Participation Modifies the Effect of a Structured Physical Activity Program on Major Mobility Disability Among Older Adults: Results From the LIFE Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2018, 73, 1501-1513.	3.9	20
149	Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors. Cardiovascular Toxicology, 2018, 18, 184-191.	2.7	10
150	Mortality implications of lower DBP with lower achieved systolic pressures in coronary artery disease. Journal of Hypertension, 2018, 36, 419-427.	0.5	5
151	TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function. Circulation Research, 2018, 122, 479-488.	4.5	50
152	Beneficial Effects of Angiotensin-(1–7) on CD34+ Cells From Patients With Heart Failure. Journal of Cardiovascular Pharmacology, 2018, 71, 155-159.	1.9	8
153	Increased human intestinal barrier permeability plasma biomarkers zonulin and FABP2 correlated with plasma LPS and altered gut microbiome in anxiety or depression. Gut, 2018, 67, 1555.2-1557.	12.1	318
154	Serotonin Transporter Gene Polymorphism in Women With Suspected Ischemia. , 2018, 2, 8-15.	0.8	1
155	Extent of coronary atherosclerosis and arterial remodelling in women: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Cardiovascular Diagnosis and Therapy, 2018, 8, 405-413.	1.7	4
156	Regenerative Medicine in the State of Florida: Letter Outlining the Florida Organization for Regenerative Medicine. Stem Cells Translational Medicine, 2018, 7, 511-512.	3.3	0
157	Optimal medical treatment of hypertension in patients with coronary artery disease. Expert Review of Cardiovascular Therapy, 2018, 16, 815-823.	1.5	4
158	Long-term mortality and estimated functional capacity among women with symptoms of ischemic heart disease: From the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2018, 206, 123-126.	2.7	5
159	Intracoronary Bolus Injection Versus Intravenous Infusion of Adenosine for Assessment of Coronary Flow Velocity Reserve in Women With Signs and Symptoms of Myocardial Ischemia and No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2018, 11, 2125-2127.	2.9	11
160	Ischemia and No Obstructive Coronary Artery Disease (INOCA): What Is the Risk?. Journal of the American Heart Association, 2018, 7, e008868.	3.7	124
161	Not All Stem Cells Are Created Equal. Circulation Research, 2018, 123, 944-946.	4.5	10
162	The gut microbiota and the brain–gut–kidney axis in hypertension and chronic kidney disease. Nature Reviews Nephrology, 2018, 14, 442-456.	9.6	413

#	Article	IF	CITATIONS
163	Hypertension in Florida: Data From the OneFlorida Clinical Data Research Network. Preventing Chronic Disease, 2018, 15, E27.	3.4	15
164	Hypertension in Ischemic Heart Disease. , 2018, , 288-297.		0
165	Gut microbiota and serum metabolite differences in African Americans and White Americans with high blood pressure. International Journal of Cardiology, 2018, 271, 336-339.	1.7	47
166	Maladaptive left ventricular remodeling in women: An analysis from the Women's Ischemia Syndrome Evaluation–Coronary Vascular Dysfunction study. International Journal of Cardiology, 2018, 268, 230-235.	1.7	3
167	Optimal Systolic Blood Pressure Target in Resistant and Non-Resistant Hypertension: A Pooled Analysis of Patient-Level Data from SPRINT and ACCORD. American Journal of Medicine, 2018, 131, 1463-1472.e7.	1.5	16
168	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Medicine, 2018, 15, e1002538.	8.4	67
169	Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial. American Heart Journal, 2018, 201, 54-62.	2.7	17
170	Cardiovascular Risks of Impaired Fertility and Assisted Reproductive Therapy. , 2018, , 79-88.		0
171	The Athena trials: Autologous adiposeâ€derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. Catheterization and Cardiovascular Interventions, 2017, 89, 169-177.	1.7	89
172	Migraine Headache and Long-Term Cardiovascular Outcomes: An Extended Follow-Up of the Women's Ischemia Syndrome Evaluation. American Journal of Medicine, 2017, 130, 738-743.	1.5	33
173	SYNTAX Score and Long-TermÂOutcomes. Journal of the American College of Cardiology, 2017, 69, 395-403.	2.8	54
174	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease. Circulation, 2017, 135, 1417-1428.	1.6	46
175	Advancements in pharmacotherapy for angina. Expert Opinion on Pharmacotherapy, 2017, 18, 457-469.	1.8	4
176	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction. Circulation Research, 2017, 120, 1947-1957.	4.5	33
177	The Gut, Its Microbiome, and Hypertension. Current Hypertension Reports, 2017, 19, 36.	3.5	103
178	Dynapenia and Metabolic Health in Obese and Nonobese Adults Aged 70ÂYears and Older: The LIFE Study. Journal of the American Medical Directors Association, 2017, 18, 312-319.	2.5	17
179	Menopausal symptoms and cardiovascular disease mortality in the Women's Ischemia Syndrome Evaluation (WISE). Menopause, 2017, 24, 126-132.	2.0	58
180	Resistant Hypertension: Mechanisms and Treatment. Current Hypertension Reports, 2017, 19, 56.	3.5	27

#	Article	IF	CITATIONS
181	Fifteen new risk loci for coronary artery disease highlight arterial-wall-specific mechanisms. Nature Genetics, 2017, 49, 1113-1119.	21.4	260
182	Gut Microbiota. Circulation Research, 2017, 120, 1724-1726.	4.5	36
183	Typical angina is associated with greater coronary endothelial dysfunction but not abnormal vasodilatory reserve. Clinical Cardiology, 2017, 40, 886-891.	1.8	7
184	CORONARY MICROVASCULAR DYSFUNCTION IS RELATED TO LEFT VENTRICULAR CONCENTRIC REMODELING AND DIASTOLIC DYSFUNCTION: FROM THE WISE-CVD STUDY. Journal of the American College of Cardiology, 2017, 69, 141.	2.8	0
185	GLOBAL LONGITUDINAL STRAIN IN PATIENTS WITH NEW LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AFTER ANTICANCER TARGETED THERAPIES. Journal of the American College of Cardiology, 2017, 69, 821.	2.8	0
186	CARDIOMYOPATHY ASSOCIATED WITH TARGETED ANTICANCER THERAPIES IN ELECTRONIC HEALTH RECORDS. Journal of the American College of Cardiology, 2017, 69, 925.	2.8	0
187	PROGNOSTIC RISK FACTORS FOR HEART FAILURE HOSPITALIZATION IN WOMEN WITHOUT OBSTRUCTIVE CORONARY DISEASE: AN ANCILLARY STUDY FROM THE WOMEN'S ISCHEMIA SYNDROME EVALUATION (WISE). Journal of the American College of Cardiology, 2017, 69, 960.	2.8	Ο
188	RELATIONSHIP BETWEEN DIASTOLIC BLOOD PRESSURE AND ALL-CAUSE MORTALITY WITH LOWER SYSTOLIC BLOOD PRESSURE AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE: LONG-TERM FOLLOW-UP OF THE US COHORT OF THE INTERNATIONAL VERAPAMIL SR-TRANDOLAPRIL STUDY (INVEST). Journal of the American College of Cardiology, 2017, 69, 1685.	2.8	0
189	Ischemia and No Obstructive Coronary Artery Disease (INOCA). Circulation, 2017, 135, 1075-1092.	1.6	527
190	Myocardial tissue deformation is reduced in subjects with coronary microvascular dysfunction but not rescued by treatment with ranolazine. Clinical Cardiology, 2017, 40, 300-306.	1.8	22
191	Cardiac Cell Therapy Evolving From Complex to Straightforward. Circulation Research, 2017, 121, 1116-1118.	4.5	2
192	Impact of Selection Bias on Estimation of Subsequent Event Risk. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	28
193	Sudden Cardiac Death in Women With Suspected Ischemic Heart Disease, Preserved Ejection Fraction, and No Obstructive Coronary Artery Disease: A Report From the Women's Ischemia Syndrome Evaluation Study. Journal of the American Heart Association, 2017, 6, .	3.7	19
194	Report of the National Heart, Lung, and Blood Institute Working Group on the Role of Microbiota in Blood Pressure Regulation. Hypertension, 2017, 70, 479-485.	2.7	53
195	Blood pressure, heart rate, and double product. Journal of Hypertension, 2017, 35, 1785-1786.	0.5	1
196	Ten-Year Mortality in the WISE Study (Women's Ischemia Syndrome Evaluation). Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	82
197	Genetic Variants Associated With Uncontrolled Blood Pressure onÂThiazide Diuretic/βâ€Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses)Âand INVEST (International Verapamilâ€SR Trandolapril Study) Trials. Journal of the American Heart Association. 2017. 6.	3.7	15
198	Quality and Equitable Health Care Gaps forÂWomen. Journal of the American College of Cardiology, 2017, 70, 373-388.	2.8	86

#	Article	IF	CITATIONS
199	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. Scientific Reports, 2017, 7, 4419.	3.3	18
200	Intestinal Permeability Biomarker Zonulin is Elevated in Healthy Aging. Journal of the American Medical Directors Association, 2017, 18, 810.e1-810.e4.	2.5	89
201	Hypertension-Linked Pathophysiological Alterations in the Gut. Circulation Research, 2017, 120, 312-323.	4.5	374
202	Predictors of Change in Physical Function in Older Adults in Response to Long-Term, Structured Physical Activity: The LIFE Study. Archives of Physical Medicine and Rehabilitation, 2017, 98, 11-24.e3.	0.9	27
203	Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. Basic Research in Cardiology, 2017, 112, 3.	5.9	16
204	Effect of Lowâ€Furanocoumarin Hybrid Grapefruit Juice Consumption on Midazolam Pharmacokinetics. Journal of Clinical Pharmacology, 2017, 57, 305-311.	2.0	4
205	Cardiovascular safety of NSAIDs: Additional insights after PRECISION and point of view. Clinical Cardiology, 2017, 40, 1352-1356.	1.8	48
206	Fertility Therapy and Long-Term Cardiovascular Risk. Journal of the American College of Cardiology, 2017, 70, 1214-1215.	2.8	8
207	Cold Pressor Stress Cardiac Magnetic Resonance Myocardial Flow Reserve Is Not Useful for Detection of Coronary Endothelial Dysfunction in Women with Signs and Symptoms of Ischemia and No Obstructive CAD. PLoS ONE, 2017, 12, e0169818.	2.5	2
208	Inflammatory biomarkers as predictors of heart failure in women without obstructive coronary artery disease: A report from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2017, 12, e0177684.	2.5	43
209	Aortic flow conditions predict ejection efficiency in the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Cardiovascular Diagnosis and Therapy, 2017, 7, 288-295.	1.7	3
210	Systolic blood pressure target: Have we identified the optimal target yet?. Journal of Public Health and Emergency, 2017, 1, 61-61.	4.4	0
211	Acetylcholine versus cold pressor testing for evaluation of coronary endothelial function. PLoS ONE, 2017, 12, e0172538.	2.5	13
212	Daily Activity Measured With Wearable Technology as a Novel Measurement of Treatment Effect in Patients With Coronary Microvascular Dysfunction: Substudy of a Randomized Controlled Crossover Trial. JMIR Research Protocols, 2017, 6, e255.	1.0	11
213	Abstract 108: Impact of a Wireless "Wearable" Device to Measure Daily Activity in Patients With Coronary Microvascular Disease Treated With Late Na Channel Inhibition (ranolazine): a Substudy of the RWISE Clinical Trial. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	2.2	0
214	Abstract 987: Unanticipated cardiotoxicity due to targeted anti-cancer therapy in hematologic malignancies patients: Natural history and risk factors. , 2017, , .		0
215	Predictors of short- and long-term mortality in hospitalized veterans with elevated troponin. Journal of Hospital Medicine, 2016, 11, 773-777.	1.4	6
216	An injectable capillary-like microstructured alginate hydrogel improves left ventricular function after myocardial infarction in rats. International Journal of Cardiology, 2016, 220, 149-154.	1.7	31

#	Article	IF	CITATIONS
217	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. American Heart Journal, 2016, 179, 142-150.	2.7	18
218	Genetic loci associated with nonobstructive coronary artery disease in Caucasian women. Physiological Genomics, 2016, 48, 12-20.	2.3	15
219	Mental Stress and Myocardial Ischemia: Young Women at Risk. Journal of the American Heart Association, 2016, 5, .	3.7	17
220	Identification of Bone Marrow Cell Subpopulations Associated with Improved Functional Outcomes in Patients with Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplantation, 2016, 25, 1675-1687.	2.5	32
221	Noninvasive Imaging toÂEvaluate Women With Stable Ischemic Heart Disease. JACC: Cardiovascular Imaging, 2016, 9, 421-435.	5.3	45
222	Reply. Journal of the American College of Cardiology, 2016, 67, 2088.	2.8	1
223	A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal, 2016, 37, 1504-1513.	2.2	152
224	Brain–Gut–Bone Marrow Axis. Circulation Research, 2016, 118, 1327-1336.	4.5	95
225	Ischemic Predictors of Outcomes in Women With Signs and Symptoms of Ischemia and Nonobstructive Coronary Artery Disease. JAMA Cardiology, 2016, 1, 491.	6.1	3
226	Circulating progenitor cells and coronary microvascular dysfunction: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation – Coronary Vascular Dysfunction Study (WISE-CVD). Atherosclerosis, 2016, 253, 111-117.	0.8	11
227	Hypertension-linked mechanical changes of rat gut. Acta Biomaterialia, 2016, 45, 296-302.	8.3	29
228	Long-Term Mortality in Hypertensive Patients With Coronary Artery Disease. Hypertension, 2016, 68, 1110-1114.	2.7	25
229	Cardiovascular Disease and 10-Year Mortality in Postmenopausal Women with Clinical Features of Polycystic Ovary Syndrome. Journal of Women's Health, 2016, 25, 875-881.	3.3	65
230	Women, Hypertension, and the Systolic Blood Pressure Intervention Trial. American Journal of Medicine, 2016, 129, 1030-1036.	1.5	50
231	Heart failure hospitalization in women with signs and symptoms of ischemia: A report from the women's ischemia syndrome evaluation study. International Journal of Cardiology, 2016, 223, 936-939.	1.7	28
232	The Promise and Challenge of InducedÂPluripotent Stem Cells forÂCardiovascular Applications. JACC Basic To Translational Science, 2016, 1, 510-523.	4.1	41
233	Autologous CD34 <sup>+</sup> Cell Therapy for Refractory Angina: 2-Year Outcomes from the ACT34-CMI Study. Cell Transplantation, 2016, 25, 1701-1711.	2.5	58
234	Experimental and early investigational drugs for angina pectoris. Expert Opinion on Investigational Drugs, 2016, 25, 1413-1421.	4.1	8

#	Article	IF	CITATIONS
235	Psychosocial predictors of long-term mortality among women with suspected myocardial ischemia: the NHLBI-sponsored Women's Ischemia Syndrome Evaluation. Journal of Behavioral Medicine, 2016, 39, 687-693.	2.1	15
236	Mortality Risk Associated With Resistant Hypertension Among Women: Analysis from Three Prospective Cohorts Encompassing the Spectrum of Women's Heart Disease. Journal of Women's Health, 2016, 25, 996-1003.	3.3	14
237	Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia. Journal of Molecular Medicine, 2016, 94, 37-49.	3.9	50
238	Safety of Routine Invasive Versus Selective Invasive Therapy in Women with Non-ST-Elevation Acute Coronary Syndrome. Cardiology and Therapy, 2016, 5, 43-50.	2.6	4
239	CES1P1 variant â^'816A>C is not associated with hepatic carboxylesterase 1 expression and activity or antihypertensive effect of trandolapril. European Journal of Clinical Pharmacology, 2016, 72, 681-687.	1.9	11
240	Stem cell therapy restores viscoelastic properties of myocardium in rat model of hypertension. Journal of the Mechanical Behavior of Biomedical Materials, 2016, 59, 71-77.	3.1	18
241	Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. Texas Heart Institute Journal, 2016, 43, 291-296.	0.3	2
242	Use of bio-informatics assessment schema (BIAS) to improve diagnosis and prognosis of myocardial perfusion data: results from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE). Cardiovascular Diagnosis and Therapy, 2016, 6, 424-431.	1.7	2
243	PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. Journal of Hypertension, 2015, 33, 2278-2285.	0.5	38
244	Relationships between components of metabolic syndrome and coronary intravascular ultrasound atherosclerosis measures in women without obstructive coronary artery disease. Cardiovascular Endocrinology, 2015, 4, 45-52.	0.8	10
245	Effects of Verapamil SR and Atenolol on 24-Hour Blood Pressure and Heart Rate in Hypertension Patients with Coronary Artery Disease: An International Verapamil SR-Trandolapril Ambulatory Monitoring Substudy. PLoS ONE, 2015, 10, e0122726.	2.5	4
246	Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. Cardiovascular Drugs and Therapy, 2015, 29, 391-401.	2.6	27
247	Cardiac Magnetic Resonance Myocardial Perfusion Reserve Index Is Reduced in Women With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Imaging, 2015, 8, .	2.6	184
248	Association of aortic stiffness and wave reflections with coronary flow reserve in women without obstructive coronary artery disease: An ancillary study from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 170, 1243-1254.	2.7	30
249	Angina treatments and prevention of cardiac events: an appraisal of the evidence: TableÂ1. European Heart Journal Supplements, 2015, 17, G10-G18.	0.1	6
250	Acute Kidney Injury after Transcatheter Aortic Valve Replacement. American Journal of Nephrology, 2015, 41, 370-371.	3.1	3
251	Assessing cardiovascular risk in women: Looking beyond traditional risk factors. Trends in Cardiovascular Medicine, 2015, 25, 152-153.	4.9	9
252	Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. Circulation Research, 2015, 116, 99-107.	4.5	65

#	Article	lF	CITATIONS
253	Multiple Causes for Ischemia Without Obstructive Coronary Artery Disease. Circulation, 2015, 131, 1044-1046.	1.6	30
254	Recognizing Sex SimilaritiesÂin Cardiovascular Disease Research. Journal of the American College of Cardiology, 2015, 65, 2152-2153.	2.8	3
255	Mild renal dysfunction and long-term adverse outcomes in women with chest pain: Results from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2015, 169, 412-418.	2.7	15
256	Gut Dysbiosis Is Linked to Hypertension. Hypertension, 2015, 65, 1331-1340.	2.7	1,079
257	The Coronary Microcirculation in STEMI: The Next Frontier?. European Heart Journal, 2015, 36, 3178-3181.	2.2	6
258	Emergence of Nonobstructive CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2015, 66, 1918-1933.	2.8	257
259	Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension — A case report. International Journal of Cardiology, 2015, 201, 157-158.	1.7	69
260	Efficacy and Safety of Angiotensin Receptor Blockers in Older Patients: A Meta-Analysis of Randomized Trials. American Journal of Hypertension, 2015, 28, 576-585.	2.0	26
261	Microvascular coronary dysfunction and ischemic heart disease: Where are we in 2014?. Trends in Cardiovascular Medicine, 2015, 25, 98-103.	4.9	27
262	Impact of Aspirin According to Type of Stable Coronary Artery Disease: Insights from a Large International Cohort. American Journal of Medicine, 2015, 128, 137-143.	1.5	7
263	Renal Function and Coronary Microvascular Dysfunction in Women with Symptoms/Signs of Ischemia. PLoS ONE, 2015, 10, e0125374.	2.5	34
264	Abstract 15465: Precision Medicine Approach to Resistant Hypertension: Genetic Markers of Resistant Hypertension Through a Genome-wide Association Study (GWAS) in the Secondary Prevention of Subcortical Strokes (SPS3). Circulation, 2015, 132, .	1.6	0
265	TIMI Frame Count and Adverse Events in Women with No Obstructive Coronary Disease: A Pilot Study from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2014, 9, e96630.	2.5	23
266	Update in Cardiology: Evidence Published in 2013. Annals of Internal Medicine, 2014, 160, 847.	3.9	0
267	Largeâ€5cale Gene entric Analysis Identifies Polymorphisms for Resistant Hypertension. Journal of the American Heart Association, 2014, 3, e001398.	3.7	32
268	A training program in cardiovascular cell-based therapy: from the NHLBI Cardiovascular Cell Therapy Research Network. Regenerative Medicine, 2014, 9, 793-797.	1.7	2
269	One-Year Follow-up of Intracoronary Stem Cell Delivery on Left Ventricular Function Following ST-Elevation Myocardial Infarction. JAMA - Journal of the American Medical Association, 2014, 311, 301.	7.4	30
270	Cardiovascular and Mortality Risk of Apparent Resistant Hypertension in Women With Suspected Myocardial Ischemia: A Report From the NHLBIâ€Sponsored WISE Study. Journal of the American Heart Association, 2014, 3, e000660.	3.7	57

#	Article	IF	CITATIONS
271	Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: An ancillary study of the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation. American Heart Journal, 2014, 167, 826-832.	2.7	33
272	A Microvascular-Myocardial Diastolic Dysfunctional State and Risk for Mental Stress Ischemia. JACC: Cardiovascular Imaging, 2014, 7, 362-365.	5.3	40
273	Detailed Analysis of Bone Marrow From Patients With Ischemic Heart Disease and Left Ventricular Dysfunction. Circulation Research, 2014, 115, 867-874.	4.5	65
274	Usefulness of Beta Blockade in Contemporary Management of Patients With Stable Coronary Heart Disease. American Journal of Cardiology, 2014, 114, 1607-1612.	1.6	21
275	2014 Hypertension Recommendations From the Eighth Joint National Committee Panel Members Raise Concerns for Elderly Black and Female Populations. Journal of the American College of Cardiology, 2014, 64, 394-402.	2.8	79
276	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	2.8	67
277	Bone Marrow Mononuclear Cell Therapy for Acute Myocardial Infarction. Circulation Research, 2014, 114, 1564-1568.	4.5	45
278	Some thoughts on the continuing dilemma of angina pectoris. European Heart Journal, 2014, 35, 1361-1364.	2.2	8
279	Comparison of low and high dose intracoronary adenosine and acetylcholine in women undergoing coronary reactivity testing: Results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE). International Journal of Cardiology, 2014, 172, e114-e115.	1.7	9
280	Depression, Dietary Habits, and Cardiovascular Events Among Women with Suspected Myocardial Ischemia. American Journal of Medicine, 2014, 127, 840-847.	1.5	23
281	The Prevalence of Microvascular Dysfunction, Its Role Among Men, and Links With Adverse Outcomes. Circulation, 2014, 129, 2497-2499.	1.6	2
282	Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. Journal of Hypertension, 2014, 32, 635-643.	0.5	88
283	Reply to †Resistant hypertension revisited. Journal of Hypertension, 2014, 32, 1547.	0.5	1
284	A Critical Analysis of Clinical Outcomes Reported in Stem Cell Trials for Acute Myocardial Infarction: Some Thoughts for Design of Future Trials. Current Atherosclerosis Reports, 2013, 15, 341.	4.8	8
285	Does expanded artificial intelligence improve the prognostic value of myocardial perfusion imaging? A report from the NHLBI-sponsored women's ischemia syndrome evaluation (WISE). Journal of Cardiovascular Magnetic Resonance, 2013, 15, P273.	3.3	0
286	Cardiovascular Care for Women: The 10-Q Report and Beyond. American Journal of Cardiology, 2013, 112, S2.	1.6	6
287	Phase II Clinical Research Design in Cardiology. Circulation, 2013, 127, 1630-1635.	1.6	44
288	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 1663-1678.	2.9	141

#	Article	IF	CITATIONS
289	Antagonist molecules in the treatment of angina. Expert Opinion on Pharmacotherapy, 2013, 14, 2323-2342.	1.8	10
290	Association Between the Chromosome 9p21 Locus and Angiographic Coronary Artery Disease Burden. Journal of the American College of Cardiology, 2013, 61, 957-970.	2.8	58
291	Adverse outcomes among women presenting with signs and symptoms of ischemia and no obstructive coronary artery disease: Findings from the National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE) angiographic core laboratory. American Heart Journal, 2013. 166. 134-141.	2.7	153
292	Calcium antagonists in the treatment of coronary artery disease. Current Opinion in Pharmacology, 2013, 13, 301-308.	3.5	12
293	Anxiety associations with cardiac symptoms, angiographic disease severity, and healthcare utilization: The NHLBI-sponsored Women's Ischemia Syndrome Evaluation. International Journal of Cardiology, 2013, 168, 2335-2340.	1.7	27
294	SENSITIVITY AND SPECIFICITY OF CMRI FOR DIAGNOSIS OF MICROVASCULAR CORONARY DYSFUNCTION IN WOMEN WITH SIGNS AND SYMPTOMS OF ISCHEMIA AND NO OBSTRUCTIVE CORONARY ARTERY DISEASE: RESULTS FROM THE NHLBI-SPONSORED WOMEN'S ISCHEMIA SYNDROME EVALUATION (WISE). Journal of the American College of Cardiology, 2013, 61, E825.	2.8	2
295	The Editor's Roundtable: The 10Q Report—Advancing Women's Heart Health Through Improved Research, Diagnosis, and Treatment. American Journal of Cardiology, 2013, 112, 1676-1687.	1.6	2
296	Lack of association of the HMGA1 IVS5-13insC variant with type 2 diabetes in an ethnically diverse hypertensive case control cohort. Journal of Translational Medicine, 2013, 11, 12.	4.4	4
297	Body composition changes and cardiometabolic benefits of a balanced Italian Mediterranean Diet in obese patients with metabolic syndrome. Acta Diabetologica, 2013, 50, 409-416.	2.5	82
298	Diminazene Aceturate Enhances Angiotensin-Converting Enzyme 2 Activity and Attenuates Ischemia-Induced Cardiac Pathophysiology. Hypertension, 2013, 62, 746-752.	2.7	109
299	Clinical Implications of the Women's Ischemia Syndrome Evaluation: Inter-Relationships Between Symptoms, Psychosocial Factors and Cardiovascular Outcomes. Women's Health, 2013, 9, 479-490.	1.5	32
300	Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human Molecular Genetics, 2013, 22, 3394-3395.	2.9	1
301	Coronary Angiography. Circulation, 2013, 127, 1760-1762.	1.6	16
302	Impact of TCF7L2 single nucleotide polymorphisms on hydrochlorothiazide-induced diabetes. Pharmacogenetics and Genomics, 2013, 23, 697-705.	1.5	12
303	Pharmacogenomic Association of Nonsynonymous SNPs in <i>SIGLEC12</i> , <i>A1BG</i> , and the Selectin Region and Cardiovascular Outcomes. Hypertension, 2013, 62, 48-54.	2.7	32
304	Effects of Pharmacologic Therapy on Health-Related Quality of Life in Elderly patients with Atrial Fibrillation: A systematic Review of Randomized and Nonrandomized Trials. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S10628.	1.8	13
305	Ankle Brachial Index Values, Leg Symptoms, and Functional Performance Among Communityâ€Dwelling Older Men and Women in the Lifestyle Interventions and Independence for Elders Study. Journal of the American Heart Association, 2013, 2, e000257.	3.7	61
306	Simple Integer Risk Score to Determine Prognosis of Patients With Hypertension and Chronic Stable Coronary Artery Disease. Journal of the American Heart Association, 2013, 2, e000205.	3.7	11

#	Article	IF	CITATIONS
307	Genetic Variation in <i>PEAR1</i> Is Associated With Platelet Aggregation and Cardiovascular Outcomes. Circulation: Cardiovascular Genetics, 2013, 6, 184-192.	5.1	97
308	Implementation of Cardovascular Cell Therapy Network trials: challenges, innovation and lessons learned from experience in the CCTRN. Expert Review of Cardiovascular Therapy, 2013, 11, 1495-1502.	1.5	3
309	Mortality Implications of Angina and Blood Pressure in Hypertensive Patients With Coronary Artery Disease: New Data From Extended Followâ€up of the International Verapamil/Trandolapril Study ( <scp>INVEST</scp> ). Clinical Cardiology, 2013, 36, 442-447.	1.8	5
310	126 CHROMOSOME 9P21 LOCUS AND ANGIOGRAPHIC CORONARY ARTERY DISEASE BURDEN: A COLLABORATIVE META-ANALYSIS. Heart, 2013, 99, A75.1-A75.	2.9	0
311	Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics. Journal of Hypertension, 2013, 31, 698-704.	0.5	63
312	Increased wave reflection and ejection duration in women with chest pain and nonobstructive coronary artery disease. Journal of Hypertension, 2013, 31, 1447-1455.	0.5	25
313	Brachial Artery Constriction during Brachial Artery Reactivity Testing Predicts Major Adverse Clinical Outcomes in Women with Suspected Myocardial Ischemia: Results from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. PLoS ONE, 2013, 8, e74585.	2.5	9
314	Number and Function of Bone-Marrow Derived Angiogenic Cells and Coronary Flow Reserve in Women without Obstructive Coronary Artery Disease: A Substudy of the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE). PLoS ONE, 2013, 8, e81595.	2.5	5
315	Enhancing the Function of CD34+ Cells by Targeting Plasminogen Activator Inhibitor-1. PLoS ONE, 2013, 8, e79067.	2.5	12
316	The Serpin Solution; Targeting Thrombotic and Thrombolytic Serine Proteases in Inflammation. Cardiovascular & Hematological Disorders Drug Targets, 2013, 13, 99-110.	0.7	19
317	Detailed analysis of polymer response to delivery balloon expansion of drug-eluting stents versus bare metal stents. EuroIntervention, 2013, 9, 389-397.	3.2	12
318	Combining Psychosocial Data to Improve Prediction of Cardiovascular Disease Risk Factors and Events. Psychosomatic Medicine, 2012, 74, 263-270.	2.0	20
319	Effect of the Use and Timing of Bone Marrow Mononuclear Cell Delivery on Left Ventricular Function After Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 308, 2380-9.	7.4	357
320	Rethinking Stable Ischemic Heart Disease. Journal of the American College of Cardiology, 2012, 60, 957-959.	2.8	26
321	Safety of Coronary Reactivity Testing in Women With No Obstructive Coronary Artery Disease. JACC: Cardiovascular Interventions, 2012, 5, 646-653.	2.9	177
322	A degradable, bioactive, gelatinized alginate hydrogel to improve stem cell/growth factor delivery and facilitate healing after myocardial infarction. Medical Hypotheses, 2012, 79, 673-677.	1.5	11
323	Microvascular dysfunction: what have we learned from WISE?. Expert Review of Cardiovascular Therapy, 2011, 9, 1491-1494.	1.5	4
324	Syndrome X and Microvascular Coronary Dysfunction. Circulation, 2011, 124, 1477-1480.	1.6	34

#	Article	IF	CITATIONS
325	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American College of Cardiology, 2011, 57, 2037-2114.	2.8	419
326	In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function: A double-blind randomized study from the National Heart, Lung and Blood Institute Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2011, 162, 678-684.	2.7	185
327	Effect of Phosphodiesterase Type 5 Inhibition on Microvascular Coronary Dysfunction in Women: A Women's Ischemia Syndrome Evaluation (WISE) Ancillary Study. Clinical Cardiology, 2011, 34, 483-487.	1.8	58
328	Effect of Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells 2 to 3 Weeks Following Acute Myocardial Infarction on Left Ventricular Function. JAMA - Journal of the American Medical Association, 2011, 306, 2110.	7.4	377
329	Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina. Circulation Research, 2011, 109, 428-436.	4.5	433
330	Stem and Progenitor Cell Therapies for Cardiovascular Disease. Journal of Cell Science & Therapy, 2011, 2, .	0.3	2
331	Combination Rosuvastatin Plus Fenofibric Acid in a Cohort of Patients 65 Years or Older With Mixed Dyslipidemia: Subanalysis of Two Randomized, Controlled Studies. Clinical Cardiology, 2010, 33, 609-619.	1.8	7
332	Endothelium as a Predictor of Adverse Outcomes. Clinical Cardiology, 2010, 33, 730-732.	1.8	25
333	An Intravascular Ultrasound Analysis in Women Experiencing Chest Pain in the Absence of Obstructive Coronary Artery Disease: A Substudy from the National Heart, Lung and Blood Institute–Sponsored Women's Ischemia Syndrome Evaluation (WISE). Journal of Interventional Cardiology. 2010. 23. 511-519.	1.2	162
334	Residual risk for secondary ischemic events in patients with atherothrombotic disease: Opportunity for future improvements in patient care. Annals of Medicine, 2010, 42, 19-35.	3.8	23
335	Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2010, 304, 61.	7.4	578
336	Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Journal of the American College of Cardiology, 2010, 55, 2825-2832.	2.8	660
337	Prognostic Value of Global MR Myocardial Perfusion Imaging in Women With Suspected Myocardial Ischemia and No Obstructive Coronary Disease. JACC: Cardiovascular Imaging, 2010, 3, 1030-1036.	5.3	94
338	A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored Women's Ischemia Syndrome Evaluation (WISE). American Heart Journal, 2010, 159, 987.e1-987.e7.	2.7	39
339	Bone marrow-derived cells and hypertension. Expert Review of Cardiovascular Therapy, 2010, 8, 1139-1148.	1.5	1
340	Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. European Heart Journal, 2009, 30, 1395-1401.	2.2	86
341	Adverse Cardiovascular Outcomes in Women With Nonobstructive Coronary Artery Disease. Archives of Internal Medicine, 2009, 169, 843.	3.8	475
342	Enhancing clinical trials on the internet: Lessons from INVEST. Clinical Cardiology, 2009, 24, V-17-V-23.	1.8	27

#	Article	IF	CITATIONS
343	The Impact of Nitric Oxide in Cardiovascular Medicine: Untapped Potential Utility. American Journal of Medicine, 2009, 122, S10-S15.	1.5	35
344	Insulin as a Cardiovascular Therapeutic: Improving Glycemic Control in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2009, 53, S1-S2.	2.8	1
345	Response to Letter by Barrios and Escobar. Stroke, 2009, 40, .	2.0	0
346	Comorbid Depression and Anxiety Symptoms as Predictors of Cardiovascular Events: Results From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Psychosomatic Medicine, 2009, 71, 958-964.	2.0	104
347	α-Adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). American Heart Journal, 2008, 156, 397-404.	2.7	45
348	Response to The J-Point Revisited. Hypertension, 2008, 51, .	2.7	0
349	Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). European Heart Journal, 2007, 29, 1327-1334.	2.2	276
350	Phytoestrogens and Coronary Microvascular Function in Women with Suspected Myocardial Ischemia: A Report from the Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of Women's Health, 2007, 16, 481-488.	3.3	6
351	Antihypertensive properties of a highâ€dose combination of trandolapril and verapamilâ€SR. Blood Pressure, 2007, 16, 6-9.	1.5	4
352	Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia: results from the NHLBI Women's Ischemia Syndrome Evaluation (WISE). Clinical Cardiology, 2007, 30, 69-74.	1.8	85
353	Dogma Disputed: Can Aggressively Lowering Blood Pressure in Hypertensive Patients with Coronary Artery Disease Be Dangerous?. Annals of Internal Medicine, 2006, 144, 884.	3.9	664
354	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S21-S29.	2.8	727
355	Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Journal of the American College of Cardiology, 2006, 47, S4-S20.	2.8	620
356	The Value of Estimated Functional Capacity in Estimating Outcome. Journal of the American College of Cardiology, 2006, 47, S36-S43.	2.8	124
357	Some Thoughts on the Vasculopathy of Women With Ischemic Heart Disease. Journal of the American College of Cardiology, 2006, 47, S30-S35.	2.8	156
358	Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 547-551.	2.8	51
359	Ischemic Heart Disease in Women. Journal of the American College of Cardiology, 2006, 47, S1-S3.	2.8	37
360	Impaired Coronary Vascular Reactivity and Functional Capacity in Women. Journal of the American College of Cardiology, 2006, 47, S44-S49.	2.8	41

#	Article	IF	CITATIONS
361	Migraines, Angiographic Coronary Artery Disease and Cardiovascular Outcomes in Women. American Journal of Medicine, 2006, 119, 670-675.	1.5	49
362	Depression Symptom Severity and Reported Treatment History in the Prediction of Cardiac Risk in Women With Suspected Myocardial Ischemia. Archives of General Psychiatry, 2006, 63, 874.	12.3	74
363	Introduction. American Journal of Cardiology, 2006, 97, 1-3.	1.6	26
364	Predictors of Development of Diabetes Mellitus in Patients With Coronary Artery Disease Taking Antihypertensive Medications (Findings from the INternational VErapamil SR-Trandolapril STudy) Tj ETQq0 0 0 rg'	BT <b>1∕@</b> verlo	ck6180 Tf 50 6
365	The Economic Burden of Angina in Women With Suspected Ischemic Heart Disease. Circulation, 2006, 114, 894-904.	1.6	299
366	Phytoestrogens and Lipoproteins in Women. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2209-2213.	3.6	26
367	Inflammation in Atherosclerosis. Circulation, 2006, 113, e728-32.	1.6	52
368	A Study of Antihypertensive Drugs and Depressive Symptoms (SADD-Sx) in Patients Treated With a Calcium Antagonist Versus an Atenolol Hypertension Treatment Strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosomatic Medicine, 2005, 67, 398-406.	2.0	47
369	Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. European Heart Journal, 2005, 27, 1408-1415.	2.2	238
370	Inflammation, endothelial cell activation, and coronary microvascular dysfunction in women with chest pain and no obstructive coronary artery disease. American Heart Journal, 2005, 150, 109-115.	2.7	34
371	Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic Angina <subtitle>A Randomized Controlled Trial</subtitle> . JAMA - Journal of the American Medical Association, 2004, 291, 309.	7.4	609
372	Clinical Outcomes in the Diabetes Cohort of the International Verapamil SR-Trandolapril Study. Hypertension, 2004, 44, 637-642.	2.7	114
373	Commentary on "New and Emerging Theories of Cardiovascular Disease― Biological Research for Nursing, 2004, 6, 17-20.	1.9	2
374	Prognosis in Women With Myocardial Ischemia in the Absence of Obstructive Coronary Disease. Circulation, 2004, 109, 2993-2999.	1.6	383
375	What Is the Optimal Blood Pressure and Drug Therapy for Patients With Coronary Artery Disease?. JAMA - Journal of the American Medical Association, 2004, 292, 2271.	7.4	13
376	Serum Amyloid A as a Predictor of Coronary Artery Disease and Cardiovascular Outcome in Women. Circulation, 2004, 109, 726-732.	1.6	379
377	Education: Nationally achievable solutions. Clinical Cornerstone, 2004, 6, 65-70.	0.7	0
378	Efficacy and safety of sildenafil citrate in men with erectile dysfunction and stable coronary artery disease. American Journal of Cardiology, 2004, 93, 147-153.	1.6	94

#	Article	IF	CITATIONS
379	Subliminal editorial conundra confounding publication of multicenter trials. American Journal of Cardiology, 2004, 94, 1268-1269.	1.6	2
380	A population-based evaluation of the thrombolysis in myocardial infarction risk score for unstable angina and non-ST elevation myocardial infarction. Clinical Cardiology, 2004, 27, 74-78.	1.8	21
381	Ischemic heart disease: Metabolic approaches to management. Clinical Cardiology, 2004, 27, 439-441.	1.8	15
382	Characteristics of contemporary patients with hypertension and coronary artery disease. Clinical Cardiology, 2004, 27, 571-576.	1.8	16
383	Abnormal Coronary Vasomotion as a Prognostic Indicator of Cardiovascular Events in Women. Circulation, 2004, 109, 722-725.	1.6	346
384	President's Page: Continuing investment in "State-of-the-Art―physician education— an ACCF program of high net worth. Journal of the American College of Cardiology, 2004, 43, 313-314.	2.8	1
385	Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Journal of the American College of Cardiology, 2004, 43, 1375-1382.	2.8	502
386	President's page: members' benevolence stretches the ACC mission well beyond U.S. borders. Journal of the American College of Cardiology, 2004, 43, 711-712.	2.8	0
387	President's page: fellow physicians: read, respond, repeat. Journal of the American College of Cardiology, 2004, 43, 891-892.	2.8	0
388	President's page: strengthening our house of cardiology. Journal of the American College of Cardiology, 2004, 43, 1721-1722.	2.8	0
389	Cardiovascular Therapies and Risk for Development of Diabetes. Journal of the American College of Cardiology, 2004, 44, 509-512.	2.8	57
390	Working group 1: How to increase the output of cardiologists. Journal of the American College of Cardiology, 2004, 44, 233-237.	2.8	3
391	President's page: Cardiology without borders: Embracing a healthy global association. Journal of the American College of Cardiology, 2004, 44, 1137-1138.	2.8	0
392	Task force 2: Investigator participation in clinical research. Journal of the American College of Cardiology, 2004, 44, 1729-1736.	2.8	5
393	STROKE OUTCOME IN HYPERTENSIVE CAD PATIENTS TREATED WITH VERAPAMIL SR- (VE) AND ATENOLOL-(AT) BASED STRATEGIES. Journal of Hypertension, 2004, 22, S114.	0.5	2
394	TRANDOLAPRIL IMPROVES CV OUTCOMES AND DECREASES RISK FOR NEW DIABETES IN HYPERTENSIVE PATIENTS WITH CAD. Journal of Hypertension, 2004, 22, S276.	0.5	0
395	DOGMA DISPUTED. Journal of Hypertension, 2004, 22, S113.	0.5	0
396	Task Force 2: Investigator Participation in Clinical Research. Circulation, 2004, 110, 2517-2524.	1.6	1

#	Article	IF	CITATIONS
397	Comparison of Effects of Nisoldipine-Extended Release and Amlodipine in Patients With Systemic Hypertension and Chronic Stable Angina Pectoris. American Journal of Cardiology, 2003, 91, 274-279.	1.6	20
398	Optimizing lipid management in patients with acute coronary syndromes. American Journal of Cardiology, 2003, 91, 30-35.	1.6	11
399	Introduction: New and emerging implications for the field of vascular biology. American Journal of Cardiology, 2003, 91, 1-2.	1.6	23
400	Effects of angiotensin-converting enzyme inhibition on transient ischemia. Journal of the American College of Cardiology, 2003, 42, 2049-2059.	2.8	42
401	A Calcium Antagonist vs a Non–Calcium Antagonist Hypertension Treatment Strategy for Patients With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2805.	7.4	1,107
402	Mental Stress–Induced Ischemia and All-Cause Mortality in Patients With Coronary Artery Disease. Circulation, 2002, 105, 1780-1784.	1.6	228
403	Mild Renal Insufficiency Is Associated With Angiographic Coronary Artery Disease in Women. Circulation, 2002, 105, 2826-2829.	1.6	101
404	Ethnicity and blood pressure control in patients with diabetes and coronary artery disease. American Journal of Hypertension, 2002, 15, A194.	2.0	0
405	Sex differences in chest pain in patients with documented coronary artery disease and exercise-induced ischemia: Results from the PIMI study. American Heart Journal, 2001, 142, 864-871.	2.7	63
406	Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. American Heart Journal, 2001, 141, 735-741.	2.7	470
407	Detailed angiographic analysis of women with suspected ischemic chest pain (pilot phase data from) Tj ETQq1 1	0.784314 1.6	rgBT /Over 238
408	Introduction: The European INVESTigators meeting. Clinical Cardiology, 2001, 24, A6-A6.	1.8	2
409	The vascular biology of hypertension and atherosclerosis and intervention with calcium antagonists and angiotensin-converting enzyme inhibitors. Clinical Cardiology, 2001, 24, V-1-V-5.	1.8	13
410	Abnormal Myocardial Phosphorus-31 Nuclear Magnetic Resonance Spectroscopy in Women with Chest Pain but Normal Coronary Angiograms. New England Journal of Medicine, 2000, 342, 829-835.	27.0	382
411	Factors Influencing Clinical Outcomes After Revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP). Journal of Cardiac Surgery, 1999, 14, 1-8.	0.7	7
412	Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction. Cardiovascular Drugs and Therapy, 1999, 13, 201-209.	2.6	13
413	Digital assessment of the epicardial electrocardiogram: Novel methodology for a core laboratory for clinical studies. Clinical Cardiology, 1999, 22, 311-315.	1.8	2
414	A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. American Journal of Cardiology, 1999, 84, 46-50.	1.6	145

#	Article	IF	CITATIONS
415	Coronary flow velocity response to adenosine characterizes coronary microvascular function in women with chest pain and no obstructive coronary disease. Journal of the American College of Cardiology, 1999, 33, 1469-1475.	2.8	181
416	Relationship among mental stress–induced ischemia and ischemia during daily life and during exercise: the Psychophysiologic Investigations of Myocardial Ischemia (PIMI) Study. Journal of the American College of Cardiology, 1999, 33, 1476-1484.	2.8	67
417	The Women's Ischemia Syndrome Evaluation (WISE) Study: protocol design, methodology and feasibility report. Journal of the American College of Cardiology, 1999, 33, 1453-1461.	2.8	328
418	Angina pectoris in a contemporary population: characteristics and therapeutic implications. TIDES Investigators. Cardiovascular Drugs and Therapy, 1998, 12, 211-216.	2.6	11
419	Clinical and detailed angiographic findings in patients with ambulatory electrocardiographic ischemia without critical coronary narrowing: Results from the asymptomatic cardiac ischemia pilot (ACIP) study. Clinical Cardiology, 1998, 21, 86-92.	1.8	1
420	Identifying high yield sources of patients with coronary artery disease for clinical trials: Lessons from the asymptomatic cardiac ischemia pilot (ACIP) experience. Clinical Cardiology, 1998, 21, 177-182.	1.8	2
421	Influence of smoking status on progression of endothelial dysfunction. Clinical Cardiology, 1998, 21, 331-334.	1.8	30
422	Verapamil use in patients with cardiovascular disease: An overview of randomized trials. Clinical Cardiology, 1998, 21, 633-641.	1.8	67
423	Clinical implications of endothelial dysfunction. Clinical Cardiology, 1998, 21, 795-799.	1.8	45
424	Plasma Volume Changes With an Acute Bout of High-Intensity Exercise in Men With Chronic Congestive Heart Failure Secondary to Coronary Artery Disease. American Journal of Cardiology, 1998, 81, 509-513.	1.6	4
425	Systemic hypertension and coronary artery disease. American Journal of Cardiology, 1998, 82, 21-24.	1.6	24
426	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: potential role in myocardial ischemia. American Journal of Cardiology, 1998, 82, 23S-27S.	1.6	19
427	The effects of angiotensin-converting enzyme inhibition on endothelial dysfunction: Potential role in myocardial ischemia. American Journal of Cardiology, 1998, 82, S23-S27.	1.6	6
428	Myocardial Ischemia as a Target for Treatment of Patients With Chronic Coronary Artery Disease. ACC Current Journal Review, 1998, 7, 23-27.	0.1	2
429	Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): an Internet-based randomized trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology, 1998, 32, 1228-1237.	2.8	144
430	How Do We Best Treat Patients With Ischemic Heart Disease?. Circulation, 1998, 98, 1985-1986.	1.6	5
431	A "Paper-less―Study on Optimal Treatment Strategies for Hypertension and CAD: Pilot Phase Data From the INternational VErapamil-trandolapril STudy (INVEST). Journal of the American College of Cardiology, 1998, 31, 211A-212A.	2.8	0
432	Endothelial dysfunction and its role in the cycle of cardiovascular disease. Canadian Journal of Cardiology, 1998, 14 Suppl D, 5D-7D.	1.7	0

Carl J Pepine

#	Article	IF	CITATIONS
433	Angiotensin-converting enzyme inhibitors in patients with atherosclerosis and preserved left ventricular function: clinical outcomes. Canadian Journal of Cardiology, 1998, 14 Suppl D, 23D-26D.	1.7	0
434	Potential Role of Angiotensinâ€Converting Enzyme Inhibition in Myocardial Ischemia and Current Clinical Trials. Clinical Cardiology, 1997, 20, II-58.	1.8	4
435	Comparison of subgroups assigned to medical regimens used to suppress cardiac ischemia (the) Tj ETQq1 1 0.7	84314 rgE 1.6	BT /Overlock
436	Ischemic, Hemodynamic, and Neurohormonal Responses to Mental and Exercise Stress. Circulation, 1996, 94, 2402-2409.	1.6	222
437	Left Ventricular, Peripheral Vascular, and Neurohumoral Responses to Mental Stress in Normal Middle-Aged Men and Women. Circulation, 1996, 94, 2768-2777.	1.6	127
438	Does the Brain Know When the Heart Is Ischemic?. Annals of Internal Medicine, 1996, 124, 1006.	3.9	9
439	The effects of ACE inhibition on ischemic cardiac events: Pump failure, reinfarction, hospitalization for angina, and ventricular tachyarrhythmias. Clinical Cardiology, 1995, 18, I-26-I-33.	1.8	1
440	Circadian Variation in Coronary Tone in Patients With Stable Angina. Circulation, 1995, 92, 3201-3205.	1.6	47
441	The Prognostic and Economic Implications of a Strategy to Detect and Treat Asymptomatic Ischemia: The Atenolol Silent Ischemia Trial (ASIST) Protocol. Clinical Cardiology, 1991, 14, 457-462.	1.8	20
442	Nicardipine, a new calcium channel blocker: Role for vascular selectivity. Clinical Cardiology, 1989, 12, 240-246.	1.8	12
443	Hemodynamic effects of high versus low-osmolar contrast media for ventriculography in severe aortic stenosis. CardioVascular and Interventional Radiology, 1988, 11, 10-13.	2.0	3
444	Factors Influencing Clinical Outcomes After Revascularization in the Asymptomatic Cardiac Ischemia Pilot (ACIP). Echocardiography, 1985, 2, 1-8.	0.9	2
445	A modified catheter system for retrograde left ventricular catheterization in aortic valve stenosis. Catheterization and Cardiovascular Diagnosis, 1985, 11, 433-439.	0.3	3
446	Plasma nitroglycerin concentrations and hemodynamic effects of sublingual, ointment, and controlled-release forms of nitroglycerin. Clinical Pharmacology and Therapeutics, 1984, 36, 765-772.	4.7	17
447	Percutaneous brachial catheterization using a modified sheath and new catheter system. Catheterization and Cardiovascular Diagnosis, 1984, 10, 637-642.	0.3	18
448	Comparison of the effects of nitroprusside and nitroglycerin on coronary size. Catheterization and Cardiovascular Diagnosis, 1983, 9, 391-399.	0.3	5
449	Echocardiographic analysis of systolic and diastolic left ventricular wall motion during transient myocardial ischemia. Journal of Clinical Ultrasound, 1981, 9, 59-65.	0.8	8
450	A New Temporary Atrial Pacing Catheter Inserted Percutaneously into the Subclavian Vein Without Fluoroscopy: A Preliminary Report. PACE - Pacing and Clinical Electrophysiology, 1981, 4, 458-463.	1.2	12

#	Article	IF	CITATIONS
451	Effects of transient regional ischemia on left ventricular diastolic function. Journal of Clinical Ultrasound, 1980, 8, 233-238.	0.8	3
452	Diagnostic tests for tricuspid insufficiency: How good?. Catheterization and Cardiovascular Diagnosis, 1979, 5, 1-6.	0.3	18
453	Demonstration of an inadvertently created aorto-coronary venous anastomosis: Evidence against the clinical effectiveness of retrograde coronary venous perfusion. Catheterization and Cardiovascular Diagnosis, 1979, 5, 367-370.	0.3	14
454	Ergonovine testing for coronary artery spasm in patients with angiographic mitral valve prolapse. Catheterization and Cardiovascular Diagnosis, 1978, 4, 265-274.	0.3	10
455	Transient asymptomatic S-T segment depression during daily activity. American Journal of Cardiology, 1977, 39, 396-402.	1.6	592
456	Effects of propranolol on coronary hemodynamic and metabolic responses to tachycardia stress in patients with and without coronary disease. Catheterization and Cardiovascular Diagnosis, 1977, 3, 47-57.	0.3	25
457	Effects of Perhexiline on Coronary Hemodynamic and Myocardial Metabolic Responses to Tachycardia. Circulation, 1974, 49, 887-893.	1.6	37
458	Effects of perhexiline on symptomatic and hemodynamic responses to exercise in patients with angina pectoris. American Journal of Cardiology, 1974, 33, 806-812.	1.6	17
459	Long-Term Observations in Patients with Angina and Normal Coronary Arteriograms. Circulation, 1973, 47, 36-43.	1.6	207